Outline of the relevant treatment protocols for patients in MRC trials AML10 and 12. More extensive details on the protocols are as published.^1,2,21  DAT indicates daunorubicin + AraC + 6-thioguanine; ADE, AraC + daunorubicin + etoposide; HLA, human leukocyte antigen; MACE, amsacrine + AraC + etoposide; MidAC, mitoxantrone + AraC; MAE, mitoxantrone + AraC + etoposide; ATRA, all trans retinoic acid; ICE, idarubicin + cytosine arabinoside + etoposide; R, randomization; and SCT, stem cell transplantation. In AML12, either a standard (S) or high (H) dose of AraC was given. Patients inAML12 received an allogeneic transplant if a suitable matched sibling donor was available or, if no donor was available, an autologous transplant.